The application of these mutants as an adjuvant therapeutic strategy to treat malignant breast tumors is promising and, since other tumors such as brain, lung, liver, cervical, bladder also show over expression of one or both of these proteins, it is expected that this future therapeutic strategy will be readapted or slightly modified to inhibit the growth and progression of all tumors overexpressing Fra-1 and/or c-Fos. Here, FOSL1 is linked to breast cancer.